Holen Sie sich die Stockscreener-App
14.16
3.53%
-0.56
Schlusskurs vom Vortag:
$14.72
Offen:
$14.7
24-Stunden-Volumen:
15,178
Relative Volume:
0.09
Marktkapitalisierung:
$950.11M
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-13.49
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
+6.05%
1M Leistung:
+3.73%
6M Leistung:
-12.29%
1J Leistung:
-22.95%
1-Tages-Spanne:
$14.02
$15.07
1-Wochen-Bereich:
$13.39
$15.64
52-Wochen-Spanne:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie PLSE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.02 | 997.54M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
586.00 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
201.74 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.20 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.59 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
41.83 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Pulse Biosciences Adds Veteran Healthtech Leader to Board - TipRanks
Pulse Biosciences appoints healthcare veteran Maria Sainz to board By Investing.com - Investing.com India
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors - The Joplin Globe
Weekly Earnings: Will Pulse Biosciences Inc. (6L8) stock outperform value peersEarnings Overview Summary & Growth Focused Entry Reports - ulpravda.ru
Will Pulse Biosciences Inc. stock reach Wall Street targetsMarket Trend Review & Real-Time Volume Trigger Notifications - ulpravda.ru
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Short Interest & Safe Entry Momentum Tips - ulpravda.ru
Why Pulse Biosciences Inc. stock remains resilient2025 Key Lessons & Daily Stock Momentum Reports - ulpravda.ru
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsMarket Weekly Review & Safe Capital Allocation Plans - ulpravda.ru
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - earlytimes.in
Chipmakers Recap: How Pulse Biosciences Inc 6L8 stock responds to bond market - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Pulse Biosciences, Inc (PLSE) Investor Outlook: Exploring A 44.74% Potential Upside - DirectorsTalk Interviews
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
Forecast Cut: Will Pulse Biosciences Inc. stock outperform tech sector in 2025July 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Growth Summary & Long-Term Capital Growth Strategies - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
FDA approves Pulse Biosciences’ atrial fibrillation trial By Investing.com - Investing.com Australia
How Pulse Biosciences Inc. stock benefits from tech adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - DonanımHaber
Short Covering: Can Pulse Biosciences Inc. stock beat market expectations this quarter2025 Top Decliners & Long-Term Growth Plans - Улправда
Pulse Biosciences wins FDA approval to begin PFA catheter study - MedTech Dive
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial - TipRanks
Pulse Biosciences IDE Approval for Atrial Fibrillation Study - TradingView — Track All Markets
[8-K] PULSE BIOSCIENCES, INC. Reports Material Event | PLSE SEC FilingForm 8-K - Stock Titan
Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Investing News Network
FDA approves Pulse Biosciences’ atrial fibrillation trial - Investing.com
Pulse Biosciences announces FDA IDE approval to initiate its nPulse cardiac catheter ablation system study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study - TradingView — Track All Markets
Will Pulse Biosciences Inc. stock outperform tech sector in 2025Market Performance Recap & Scalable Portfolio Growth Ideas - Улправда
Pulse Biosciences Earnings Notes - Trefis
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
0.83%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):